AFT Pharmaceuticals (NZE:AFT, ASX:AFP) expects to achieve record sales of more than AU$200 million in fiscal 2025, up from AU$56 million in fiscal 2015 and AU$106 million in fiscal 2020, according to a Monday filing with the Australian and New Zealand bourses.
The upbeat outlook comes despite sales disruptions seen in the first half. The pharmaceutical company said it targets to achieve AU$300 million turnover on a rolling annual basis by the end of 2027.
AFT Pharmaceuticals' Kiwi shares were up past 1% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.